Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.
Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.
At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.
Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.
Quanterix's product lineup is diverse and includes:
- Simoa platform
- Assay Kits
- LDTs & Assay Services
- Simoa p-Tau 217
- Simoa NfL LDT
- Simoa p-Tau 181 LDT
- HD-X Automated Immunoassay Analyzer
- SR-X Biomarker Detection System
- SP-X Imaging and Analysis System
- Simoa Accelerator Laboratory
- Homebrew - Custom Assay Development
- Uman NF-Light
The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.
Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.
Quanterix (NASDAQ: QTRX) has disclosed operational and preliminary financial results for Q4 and FY 2020. The company thrived despite pandemic challenges, pivoting to develop COVID-19 testing solutions, including an $18.2M NIH contract. Key operational milestones include FDA Emergency Use Authorizations for its antigen tests and significant advancements in neurology biomarkers. Q4 GAAP revenue is projected at $24-26 million, with non-GAAP revenue expected to rise by 32%, totaling $20-22 million. The company raised $97.6 million through a follow-on offering, enhancing its financial position for future growth.
Quanterix Corporation (NASDAQ:QTRX) received FDA Emergency Use Authorization for its Simoa® SARS-CoV-2 N Protein Antigen Test, which detects the SARS-CoV-2 virus nucleocapsid protein. The test shows 97.7% sensitivity and 100% specificity within 14 days post-symptom onset. Intended for nasopharyngeal samples, Quanterix plans to expand to other sample types. This initiative is part of the NIH-funded RADx program to enhance SARS-CoV-2 testing capacity in the U.S. Additionally, Quanterix launched the SARS-CoV-2 N Protein Antigen Advantage Assay for research use.
Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Kevin Hrusovsky, will present on the company's growth at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 p.m. EST. This marks Hrusovsky's fifth consecutive year presenting at this conference. The live webcast will be accessible for attendees and the public. Quanterix focuses on advancing precision health through digitizing biomarker analysis, aiming for earlier disease detection and improved treatment methodologies across multiple therapeutic areas, including oncology and neurology.
Quanterix Corporation (NASDAQ: QTRX) announced that the FDA granted Emergency Use Authorization (EUA) for its Simoa® Semi-Quantitative SARS-CoV-2 IgG Antibody Test, which operates on the Simoa HD-X Analyzer. This test measures the antibody response to the coronavirus spike protein and is vital for assessing immunity from COVID-19 vaccines and previous infections. Clinical studies indicate a sensitivity of 100% and specificity of 99.2%, supporting its reliability. Quanterix aims to aid COVID-19 immunology studies and enhance disease detection.
Quanterix Corporation (NASDAQ: QTRX) has appointed William Geist as Chief Operating Officer, effective November 16, 2020. Geist, with over 25 years of experience, previously led major business units at Thermo Fisher Scientific. His focus will be on enhancing Quanterix’s ultrasensitive Simoa® technology and expanding its applications across various therapeutic areas, including COVID-19, Immunology, and Oncology. This strategic hire aims to leverage his operational expertise to drive growth and innovation within the company, reinforcing Quanterix’s position in precision health.
Quanterix Corporation (NASDAQ: QTRX) announced that Chairman and CEO, Kevin Hrusovsky, will participate in a virtual fireside chat at the Canaccord Medical Technologies and Diagnostics Forum on November 19 at 10:30 a.m. EST. This engagement will include one-on-one and group meetings with institutional investors. A live webcast will be available on the Quanterix investor relations page, with replays accessible for 90 days thereafter. Quanterix is focused on advancing precision health through its digital health solution, Simoa.
908 Devices announced the appointment of Kevin Hrusovsky as Chairman of its Board of Directors. Hrusovsky, a veteran in biotechnology and CEO of Quanterix (NASDAQ: QTRX), brings extensive experience in commercializing disruptive healthcare technologies. His leadership is expected to bolster 908 Devices’ mission of democratizing mass spectrometry for critical applications in life sciences, bioprocessing, and forensics. Hrusovsky's commitment to transforming healthcare through advanced analytical tools positions the company well at a pivotal moment for next-gen proteomics.
Quanterix Corporation (NASDAQ: QTRX) announced it will release its third-quarter 2020 financial results on November 5, 2020, after the market closes. A conference call hosted by CEO Kevin Hrusovsky will take place at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the call by dialing the provided numbers or through a live webcast available on Quanterix's website for a year post-call. The company specializes in advanced biomarker analysis to enhance precision health, focusing on various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Kevin Hrusovsky, will present at the Precision Medicine Leaders Summit's Precision Oncology Conference today at 3:15 p.m. EDT. His keynote, titled “Revolutionizing Cancer Treatment and Detection with Biomarkers,” will highlight advances in multiplex assays that enable the identification of multiple oncology biomarkers simultaneously. This technology allows for early cancer detection and enhances the efficacy of immuno-oncology treatments. For more details, visit www.quanterix.com.
Quanterix Corporation (NASDAQ: QTRX) announced a Phase 2 contract with the National Institutes of Health, valued at $18.2 million, to advance a novel SARS-CoV-2 antigen test utilizing their Simoa technology. This funding supports clinical validation and aims for emergency use authorization submissions with the FDA. The contract also facilitates expanded manufacturing capacities at Quanterix's Billerica, Massachusetts facility. Initial feasibility of the test was previously supported by a Phase 1 award. The contract period extends through September 2021.
FAQ
What is the current stock price of Quanterix Corporation (QTRX)?
What is the market cap of Quanterix Corporation (QTRX)?
What is the core technology of Quanterix Corporation?
What are some applications of Quanterix's technology?
Who founded Quanterix Corporation?
What product platforms does Quanterix offer?
What makes Quanterix's diagnostic platform unique?
Is Quanterix publicly traded?
What significant achievements has Quanterix made recently?
What fluids can Quanterix's platforms detect biomarkers in?
Does Quanterix offer custom assay development?
What is the Simoa Accelerator Laboratory?
